Security Snapshot

BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) Institutional Ownership

CUSIP: 09058V103

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

246

Shares (Excl. Options)

184.6MFull value: 184,603,615 · shares · 30 Sep 2026

Price

$8.33

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-17,109,851
Value change
-$188,795,115
Number of holders
246
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
256,133,583
SEC-reported price per share
$8.37
Insider filing price
$8.37
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share is tracked under CUSIP 09058V103.
  • 246 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 320 to 246 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $2.61BFull value: $2,614,660,309 · USD · 30 Jun 2026
    to
    $1.54BFull value: $1,537,653,005 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 246 institutions filings for Q3 2026.

Open SEC evidence

Security key

09058V103

13F reference period

Q3 2026

13F holders

246

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
BCRX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.4% $143,714,288 17,483,490 BlackRock, Inc. 31 Mar 2025
Flynn James E 6.8% +17% $109,278,420 +$16,550,640 14,341,000 +18% Deerfield Mgmt, L.P. 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $123,390,357 12,961,172 Vanguard Capital Management 31 Mar 2026
STATE STREET CORP 4.8% -20% $99,215,905 -$23,376,256 12,294,412 -19% STATE STREET CORPORATION 30 Sep 2026
Avoro Capital Advisors LLC 4.2% $71,514,000 8,700,000 Avoro Capital Advisors LLC 31 Mar 2025
As of 30 Sep 2026, 246 institutional investors reported holding
184.6MFull value: 184,603,615 · shares · 30 Sep 2026
shares of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX). This represents 72% of the company’s total
256.13MFull value: 256,133,583 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
56%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
DEERFIELD MANAGEMENT COMPANY, L.P. 6% 15,490,928 2% $129,039,430
STATE STREET CORP 4.8% 12,294,412 0% $102,412,452
VANGUARD CAPITAL MANAGEMENT LLC 4.4% 11,266,982 0% $93,853,960
TCG Crossover Management, LLC 4.3% 11,020,968 2.6% $91,804,663
VANGUARD PORTFOLIO MANAGEMENT LLC 4.1% 10,533,324 0% $87,742,589
PERCEPTIVE ADVISORS LLC 4% 10,301,888 1.6% $85,814,727
Janus Henderson Group Ltd. 4% 10,257,943 0.04% $85,310,859
TWO SIGMA INVESTMENTS, LP 2.8% 7,202,757 0.04% $59,998,966
Jones Hill Capital LP 2.8% 7,083,300 10% $59,003,889
Aberdeen Group plc 2.5% 6,468,726 0.07% $53,884,488
GEODE CAPITAL MANAGEMENT, LLC 2.4% 6,050,426 0% $50,410,847
BANK OF AMERICA CORP /DE/ 2.1% 5,429,352 0% $45,226,502
GOLDMAN SACHS GROUP INC 1.7% 4,233,277 0% $35,263,195
Frazier Life Sciences Management, L.P. 1.6% 4,009,240 0.83% $33,396,969
Kynam Capital Management, LP 0.98% 2,522,660 1.2% $21,013,758
Fisher Asset Management, LLC 0.96% 2,448,598 0.01% $20,396,819
RICE HALL JAMES & ASSOCIATES, LLC 0.89% 2,268,561 1% $18,897,113
Nantahala Capital Management, LLC 0.82% 2,101,257 0.98% $17,503,471
RENAISSANCE TECHNOLOGIES LLC 0.81% 2,066,160 0.02% $17,211,113
STIFEL FINANCIAL CORP 0.71% 1,826,087 0.01% $15,211,307
VANGUARD FIDUCIARY TRUST CO 0.66% 1,700,559 0% $14,165,656
Invesco Ltd. 0.63% 1,604,864 0% $13,368,516
ORBIMED ADVISORS LLC 0.59% 1,506,000 0.23% $12,544,980
Legal & General Group Plc 0.56% 1,436,190 0% $11,963,462
DIMENSIONAL FUND ADVISORS LP 0.53% 1,361,884 0% $11,344,494

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 184,603,615 $1,537,653,005 -$188,795,115 $8.33 246
2026 Q2 261,573,978 $2,614,660,309 +$122,013,453 $10.00 320
2026 Q1 250,547,603 $2,384,873,063 +$377,134,445 $9.52 304
2025 Q4 212,542,303 $1,657,283,429 +$104,832,674 $7.80 274
2025 Q3 194,102,191 $1,473,118,671 -$35,936,486 $7.59 282
2025 Q2 197,129,798 $1,766,723,682 +$203,493,373 $8.96 292
2025 Q1 174,435,511 $1,308,746,834 +$63,398,447 $7.50 273
2024 Q4 167,662,220 $1,261,171,584 -$40,361,715 $7.52 256
2024 Q3 173,102,982 $1,315,577,234 -$13,496,556 $7.60 255
2024 Q2 174,343,886 $1,077,260,403 -$26,171,848 $6.18 238
2024 Q1 179,854,267 $913,665,406 +$14,530,963 $5.08 235
2023 Q4 176,879,832 $1,059,530,995 -$13,874,803 $5.99 234
2023 Q3 175,748,697 $1,244,274,073 +$20,781,164 $7.08 229
2023 Q2 174,092,743 $1,225,943,210 +$15,794,543 $7.04 233
2023 Q1 170,682,621 $1,423,483,184 +$98,954,044 $8.34 237
2022 Q4 157,670,070 $1,809,819,957 +$89,114,288 $11.48 225
2022 Q3 149,200,472 $1,879,908,994 -$39,491,355 $12.60 218
2022 Q2 151,882,406 $1,606,941,793 +$202,016,904 $10.58 207
2022 Q1 127,644,333 $2,074,127,946 +$162,394,498 $16.26 219
2021 Q4 118,034,837 $1,624,605,826 +$189,498,647 $13.85 197
2021 Q3 103,285,294 $1,484,281,647 -$23,674,937 $14.37 191
2021 Q2 104,615,646 $1,653,902,810 +$25,597,252 $15.81 190
2021 Q1 104,536,942 $1,063,154,138 -$141,911,795 $10.17 183
2020 Q4 120,536,116 $897,922,105 -$43,570,187 $7.45 172
2020 Q3 127,504,811 $438,191,012 -$23,494,376 $3.44 150
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .